ConductScience.org, home

Trial · NCT02563353

Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChanges in the BMD, Bone Mineral Density of hip and spine region (Hologic DXA machine)at the time the participants start treatment and in an interval as close as possible to after 6, 12, 18, 24 months from baselineDXA scan of hip and spine regions, BMD (g/cm\^2)
SecondaryChanges in the Bone microarchitecture at the tibiaat the time the participants start treatment and in an interval as close as possible to after 6, 12, 18 and 24 months from baselineHRpQCT assesses parameters of bone microarchitecture at the tibia.
SecondaryChanges in the Bone microarchitecture at the radiusat the time the participants start treatment and in an interval as close as possible to after 6, 12, 18 and 24 months from baselineHRpQCT assesses parameters of bone microarchitecture at the radius.
Secondarychanges in muscle massat the time the participants start treatment and in an interval as close as possible to after 12 and 24 months from baselineFull body DXA
SecondaryChanges from baseline in the markers of bone resorptionat the time the participants start treatment and in an interval as close as possible to after 3, 6, 12, 18, 24 months from baselineCTX, sclerostin
SecondaryChanges from baseline in the markers of bone formationat the time the participants start treatment and in an interval as close as possible to after 3, 6, 12, 18, 24 months from baselineP1NP
SecondaryChanges in Muscle strengthat the time the participants start treatment and in an interval as close as possible to after 3,6,12,18 and 24 months from baselineMeasurements of muscle strength (leg extensor power)
SecondaryChanges in handgrip strengthat the time the participants start treatment and in an interval as close as possible to after 3,6,12,18 and 24 months from baselineMeasurements of muscle strength (handgrip strength)
SecondaryChanges in Balanceat the time the participants start treatment and in an interval as close as possible to after 3, 6 ,12, 18 and 24 months from baselineShort Physical Performance Battery (SPPB)
SecondaryAdherence to WBVDuring 2 years from the start of the treatmentSelf Reporting training log
SecondaryChanges in physical activityat the time the participants start treatment and in an interval as close as possible to after 12, and 24 months from baselineIPAQ short version
SecondaryChanges in quality of lifeat the time the participants start treatment and in an interval as close as possible to after 12, and 24 months from baselineEQ5D questionaire.
SecondaryChanges in basic mobilityat the time the participants start treatment and in an interval as close as possible to after 3,6,12,18 and 24 months from baselineTime up and go test
SecondaryChanges in The Falls Efficacy Scale Internationalat the time the participants start treatment and in an interval as close as possible to after 12, and 24 months from baselineFES-I

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02563353/registered